Abstract: A method for aseptic and automatic transfer of unsealed pharmaceutical containers (2), which have been aseptically filled with a pharmaceutical preparation (5), from a filling device (6) to a subsequent unit (4), is described and comprises the steps of:a) introducing a sterile inert protective gas (3) into a transportable chamber (1),b) inserting the chamber (1) into the filling device (6),c) introducing the pharmaceutical containers (2) into the chamber (1) and closing the chamber (1), andd) transporting the chamber (1) to the subsequent unit (4), in which the pharmaceutical containers (2) are removed from the chamber (1), said protective gas (3) being continuously and evenly distributed in steps b)-d) over the unsealed pharmaceutical containers (2).

Abstract: A new pharmaceutical formulation comprising the thrombin inhibitor HOOC--CH.sub.2 --(R)-Cgl-Aze-Pab in combination with one or more absorption enhancing agents, a process for the preparation of such a pharmacutical formulation, the use of such a formulation in the treatment of thromboembolism as well as a method of treating a patient in need of antithrombotic treatment and thromboembolism by using said formulation.

Abstract: The invention relates to a surgical drill made of metal, for instance made of surgical grade stainless steel or carbon steel, intended for use when implanting cylindrical implants into bone tissue, preferably dental implants made of titanium. The body (3) of the drill (1) is coated by a thin layer of titanium nitride (TiN). The layer of titanium nitride is brightly colored and circumferential bands (8, 9, 10, 11) having a darker color have been etched around the envelope surface of the body (3) of the drill, said bands (8, 9, 10, 11) being located at predetermined distances from each other and having predetermined widths.

Abstract: There are provided novel compounds of formula I ##STR1## wherein D represents alkyl C1 to 6;T represents a C.sub.3-5 saturated or unsaturated alkylene chain substituted by --(CH.sub.2).sub.m --NXY; --O--(CH.sub.2).sub.2 --NH-- substituted by --(CH.sub.2).sub.m --NXY; or --U--(CH.sub.2).sub.a --N(X)--(CH.sub.2).sub.b --;and a, b, m, X and Y are as defined in the specification together with processes for their preparation, compositions containing them and their use in therapy. Compounds of formula I are expected to be useful inter alia in the treatment of neurodegenerative disorders.

Abstract: Controlled release beads containing a core around which is a drug-containing layer e.g. a layer containing furosemid and a process for their preparation and their use in a pharmaceutical preparation. The controlled release beads have excellent mechanical and release characteristics.

Abstract: A method is disclosed for treatment or prophylaxis of venous thrombosis employing the peptide HOOC--CH.sub.2 --(R)Cgl--aze--Pab or a stereoisomer thereof or a physiologically acceptable salt thereof.

Abstract: The invention concerns pharmaceutical preparations for stimulation of the immune system which comprise a cystine derivative as active ingredient.

Abstract: The invention concerns the compounds of the formulas: ##STR1## and protected forms and salts thereof which serve as starting materials in an improved method of synthesizing serine protease inhibitors. The invention further concerns an improved method for synthesizing serine protease inhibitors which utilizes the compounds.

Abstract: A compound of formula (II), either as a single enantiomer or in an enantiomerically enriched form ##STR1## wherein: ##STR2## and ##STR3## (wherein N in the benzimidazole moiety of Het.sub.2 means that one of the carbon atoms substituted by any one of R.sub.6 to R.sub.9 optionally may be exchanged for an unsubstituted nitrogen atom; R.sub.1, R.sub.2 and R.sub.3 are the same or different and selected from hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenylalkyl, phenylakoxy; R.sub.4 and R.sub.4, are the same or different and selected from hydrogen, alkyl, aralkyl; R.sub.5 is hydrogen, halogen, trifluoromethyl, alkyl, alkoxy; R.sub.6 -R.sub.9 are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl or adjacent groups R.sub.6 -R.sub.

Abstract: Device for mixing a pharmaceutical composition stored in a chamber (44) in said device with an agent to be added shortly before administration to form a preparation to be adminstered. The device should be capable of being shaken without leaking. It comprises a hollow body (2) having an outlet (4) sealed by a removable closure (12) and a plunger (6), which is slidable therein in sealing contact with the inner wall of the hollow body (2). The plunger (6), the hollow body (2) and the removable closure (12) define said chamber (44). An actuating means (22) is connected to the plunger (6) for displacing the same in the hollow body (2). A filling conduit (19) for said agent is connected to the chamber (44). A check valve (30) is associated with the conduit (19) and the chamber (44), which prevents flow from the chamber (44) but permits flow into said chamber through said conduit (19).

Abstract: The present invention relates to novel polypeptides which are variants of Bile Salt-Stimulated Lipase (BSSL; EC 3.1.1.1). It also relates to DNA molecules encoding the said polypeptides, and to subproducts comprising the said DNA molecules. The invention further relates to processes for producing the said BSSL variants and for producing transgenic non-human mammals capable of expressing the BSSL variants.Furthermore the invention relates to such transgenic animals as well as to infant formulas comprising milk from such transgenic animals. The invention also relates to pharmaceutical compositions comprising the said polypeptides; and the use of the said polypeptides and DNA molecules for the manufacture of medicaments.

Abstract: A new pharmaceutical multiple unit tableted dosage form containing as active ingredient an acid labile H.sup.+ K.sup.+ -ATPase inhibitor or an alkaline salt thereof or one of its single enantiomers or an alkaline salt thereof, a method for the manufacture of such a formulation, and the method of treatment with such a formulation in medicine.

Abstract: The invention relates to new competitive inhibitors of thrombin, their synthesis, pharmaceutical compositions containing the compounds as active ingredients, and the use of the compounds as anticoagulants for prophylaxis and treatment of thromboembolic diseases, according to the formula ##STR1## wherein A represents a methylene group, an ethylene group or a propylene group, which may be substituted orA represents --CH.sub.2 --O--CH.sub.2 --, --CH.sub.2 --S--CH.sub.2 --, --CH.sub.2 --SO--CH.sub.2 --, orA represents --CH.sub.2 --O--, --CH.sub.2 --S--, --CH.sub.2 --SO--, with the heteroatom functionality in position 4, orn is an integer 2 to 6; andB represents --N(R.sup.6)--C(NH)--NH.sub.2, wherein R.sup.6 is H or a methyl group, orB represents --S--C(NH)--NH.sub.2, or --C(NH)--NH.sub.2.

Abstract: Novel heterocyclic compounds having a structure according to general formula (1), pharmaceutically acceptable acid addition salts and solvates thereof are described as having a pharmacological profile showing potential for treatment of acute and chronic neuropsychiatric disorders which are known as progressively deteriorating conditions leading to neuronal cell death and dysfunction. Pharmaceutical formulations are described as containing said therapeutic compounds.

Abstract: A therapeutic preparation for inhalation which comprises insulin and a substance which enhances the absorption of insulin in the lower respiratory tract, is provided in the form of a powder preparation suitable for inhalation.

Abstract: A dry powder inhalation device comprising a housing defining a chamber in communication with a patient port in the form of a mouthpiece or nasal adaptor, and an elongate carrier bearing a powdered medicament, the device being constructed and arranged such that areas of predetermined size of the elongate carrier may sequentially be exposed within the chamber, the device comprising one or more air inlets such that when a patient inhales through the patient port an air flow is established from the air inlet(s) to the patient port through the chamber such that particles of the powdered medicament of respirable size from said exposed area of the elongate carrier are entrained within the air flow.

Abstract: The invention relates to a hip joint prosthesis comprising an attachment part for a ball unit (18) being designed to be anchored in the neck of a human femur (collum femoris), said attachment part, which is intended to be inserted into a channel (5, 14) extending through the femoral collum, being provided with parts for carrying a ball or caput (18) intended to be attached to the collum after removal of the head of the collum. The attachment part also comprises a fixture part comprising two main parts, a first part (1) which is to extend through a bore-hole (5) from the collum femoris towards the outer side of the femur and a second part (2) intended to fit into a cylindrical cavity cut into the cancellous bone of the collum.

Abstract: A pharmaceutical emulsion for intravenous administration is disclosed which comprisesa) a short acting dihydropyridine compound;b) a lipid phase;c) an emulsifier andd) water or a buffer.

Abstract: A method is disclosed for treatment or prophylaxis of arterial thrombosis employing the compound HOOC-CH.sub.2 -(R)Cha-Pic-Nag or a stereoisomer thereof or a physiologically acceptable salt thereof.